Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

To review safety and efficacy of TTI-101 plus Pembrolizumab in patients the Recurrent and Metastatic head and Neck Squamous Cell Carcinoma.

开始日期2025-12-31

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

NCT05845307

/ Not yet recruiting早期临床1期IIT

Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

To learn if TTI-101 can reduce the growth of HPV-negative squamous cell carcinomas of the head and neck when given before standard of care surgery.

开始日期2024-10-31

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+2]

NCT06141031

/ Suspended临床1/2期IIT

Phase 1/2 Trial of Radiotherapy in Combination with TTI-101 in Patients with Borderline Resectable Pancreatic Cancer

To evaluate the safety, tolerability, and efficacy of TTI-101 given in combination with Stereotactic Body Radiation Therapy (SBRT) in borderline resectable pancreatic ductal adenocarcinoma.

开始日期2024-01-16

申办/合作机构

University of Colorado Denver

[+1]

100 项与 C-188-9 相关的临床结果

登录后查看更多信息

100 项与 C-188-9 相关的转化医学

登录后查看更多信息

100 项与 C-188-9 相关的专利（医药）

登录后查看更多信息

项与 C-188-9 相关的文献（医药）

2025-04-01·THERIOGENOLOGY

IL-11 regulates the biosynthesis of PGE2 through JAK1/STAT3 signaling pathway in bovine granulosa cells

Article

作者: Yang, Liguo ; Liang, Aixin ; Liu, Mingxiao ; Zheng, Xiaoxue ; Sun, Peihao ; Wu, Hanxiao ; Zhou, Shuo

Ovulation is a highly organized and multifaceted series of events, which parallels with inflammatory processes. Prostaglandins (PGs) have been shown to play an important role in the modulation of ovulation. Our previous study revealed that Interleukin 11 (IL-11) signaling is critical in regulating steroidogenesis in bovine granulosa cells (GCs). However, the precise roles of IL-11 in the regulation of PGs remain unclear. In the present study, we investigated the effects and underlying molecular mechanisms of IL-11 on the production of PGs in primary bovine GCs. At LH-induced levels, we observed that 10 ng/mL IL-11 significantly increased prostaglandin E2 (PGE2) production via upregulating the expression of prostaglandin-endoperoxide synthase 2 (PTGS2), while IL-11 treatment did not affect the production of prostaglandin F2α (PGF2α). Furthermore, 10 ng/mL IL-11 treatment activated the phosphorylation of Janus kinase 1 (JAK1) and signal transducer and activator of transcription 3 (STAT3), which was accompanied by STAT3 nuclear translocation. Additionally, these effects were inhibited by the addition of the STAT3-specific inhibitor C188-9. Specifically, C188-9 treatment blocked the IL-11-induced STAT3 nuclear translocation, downregulated the mRNA and protein expression levels of PTGS2, and ultimately led to a reduction in PGE2 production induced by 10 ng/mL IL-11. Our findings elucidate the cellular and molecular mechanisms by which IL-11 regulates PGE2 expression through the JAK1/STAT3 signaling pathway in bovine GCs in the presence of LH, contributing to a better understanding of the ovulatory process.

2025-03-17·CLINICAL CANCER RESEARCH

Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors

Article

作者: Tweardy, David J. ; Vining, David J. ; Larson, Jeffrey ; Cartwright, Carrie ; de Achaval, Sofia ; Arora, Sukeshi P. ; Kauh, John ; Avritscher, Rony ; Alibhai, Imran ; Tsimberidou, Apostolia M. ; Kaseb, Ahmed O.

Abstract:

Purpose::

Signal transducer and activator of transcription 3 is a transcription factor that is essential for the survival and immune sequestration of cancer cells. We conducted a phase I study of TTI-101, a first-in-class, selective small-molecule inhibitor of signal transducer and activator of transcription 3, in patients with advanced metastatic cancer.

Patients and Methods::

Patients were treated with TTI-101 orally twice daily in 28-day cycles at four dose levels (DL): 3.2 (DL1), 6.4 (DL2), 12.8 (DL3), and 25.6 (DL4) mg/kg/day (“3+3” design). Three TTI-101 formulations were used in a stepwise manner (NCT03195699).

Results::

Sixty-four patients were treated (median age, 63 years; male sex, 52%; median number of prior therapies, 3). No dose-limiting toxicities or fatal treatment-related adverse events (TRAE) were observed. Diarrhea (mostly grade 1/2) was the only TRAE observed in ≥30% of subjects. Five patients experienced grade 3 TRAEs that resolved. TTI-101 showed linear pharmacokinetics from DL1 to DL3, with the pharmacokinetics plateauing at DL3. The recommended phase II dose is 12.8 mg/kg/day (DL3). Of the 41 patients who were evaluable for response, five (12%) had confirmed partial responses (cPR) and 17 (41%) had stable disease. Three (18%) of the 17 patients with hepatocellular carcinoma had a cPR (median time to treatment failure, 10.6 months). Two other cPRs were noted in one patient with ovarian cancer and one patient with gastric cancer.

Conclusions::

TTI-101 was well tolerated. cPRs were observed across tumor types. The antitumor activity of TTI-101 monotherapy in patients with advanced, metastatic solid tumors is promising. A phase II study of TTI-101 in hepatocellular carcinoma is currently underway.

2024-12-01·CANCER CELL

Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy

Article

作者: Gao, Qiang ; Li, Qian ; Miao, Beiping ; Wang, Hui ; Xu, Nuo ; Zheng, Quan ; Qin, Wenxin ; Zhang, Sisi ; Zhang, Haoyu ; Ji, Shuyi ; Tang, Xiangyu ; Li, Yan ; Zhu, Chuchen ; Sun, Chong ; Xu, Lei ; Li, Botai ; Zhu, Lili ; Hu, Haiyan ; Zhu, Chunchao ; Xia, Yuhan ; Yu, Chune ; Yang, Chen ; Wang, Cun ; Geng, Haigang ; Wang, Hongye ; Jin, Guangzhi ; Yang, Xupeng ; Yuan, Shengxian ; Ma, Xuhui ; Liu, Zhicheng ; Du, Shangce ; Zhang, Tangansu ; Leng, Chao ; Chen, Xiaoping ; Cao, Ying ; Huang, Zhao ; Bernards, René ; Feng, Hao

Tumor-initiating cells (TICs) possess the ability to evade anti-tumor immunity, potentially explaining many failures of cancer immunotherapy. Here, we identify CD49f as a prominent marker for discerning TICs in hepatocellular carcinoma (HCC), outperforming other commonly used TIC markers. CD49f-high TICs specifically recruit tumor-promoting neutrophils via the CXCL2-CXCR2 axis and create an immunosuppressive milieu in the tumor microenvironment (TME). Reciprocally, the neutrophils reprogram nearby tumor cells toward a TIC phenotype via secreting CCL4. These cells can evade CD8⁺ T cell-mediated killing through CCL4/STAT3-induced and CD49f-stabilized CD155 expression. Notably, while aberrant CD155 expression contributes to immune suppression, it also represents a TIC-specific vulnerability. We demonstrate that either CD155 deletion or antibody blockade significantly enhances sensitivity to anti-PD-1 therapy in preclinical HCC models. Our findings reveal a new mechanism of tumor immune evasion and provide a rationale for combining CD155 blockade with anti-PD-1/PD-L1 therapy in HCC.

项与 C-188-9 相关的新闻（医药）

2025-03-25

·GlobeNewswire-Health Care

Tvardi Therapeutics Announces Publication of Results from First-in-Human Study of TTI-101 in Patients with Advanced Solid Tumors in the Journal Clinical Cancer Research

Tvardi’s previously announced merger with publicly traded Cara Therapeutics is on-track to close in 1H 2025 TTI-101 is currently being evaluated in a Phase 2 study in patients with idiopathic pulmonary fibrosis (REVERTIPF) and a Phase 2 study in patients with hepatocellular carcinoma (REVERTLIVER CANCER) March 19, 2025 -- Tvardi Therapeutics, Inc. (“Tvardi”), a clinical-stage biopharmaceutical company developing novel STAT3 inhibitors for fibrosis-driven diseases, announced today that results from the first-in-human Phase 1 study of TTI-101 in patients with advanced solid tumors have been published in the journal Clinical Cancer Research. Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi Therapeutics, stated, “The positive results of this Phase 1 study speak to the potential broad clinical utility of our lead candidate, TTI-101, across a range of fibrosis-driven diseases in which STAT3-mediated proliferation is implicated. Perhaps most notable, in addition to its biological activity in advanced treatment-refractory hepatocellular carcinoma, was a pharmacodynamic reduction of TTI-101’s target, activated STAT3, within paired tumor biopsies. We believe these findings provide very strong rationale for our ongoing Phase 2 studies in IPF and liver cancer.” The publication, titled, “Phase 1 Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors,” describes a Phase 1 study in which patients, who received a median of three prior systemic therapies, were treated with TTI-101 monotherapy orally twice daily (NCT03195699). By targeting both intrinsic tumorigenesis and extrinsic immune suppression, TTI-101 showed promising antitumor activity across tumor types, particularly in patients with hepatocellular carcinoma who were refractory to immune checkpoint inhibitors and anti-angiogenic agents. TTI-101 showed dose-linear pharmacokinetics and, at the recommended Phase 2 dose, the trough exposure levels were above the IC90 for STAT3-induced growth. No dose-limiting toxicities or treatment-related adverse events greater than grade 3 were observed. Pharmacodynamic analysis demonstrated TTI-101 decreased levels of phosphotyrosine (pY) STAT3 within paired tumor biopsies. Tvardi is a clinical stage, biopharmaceutical company focused on the discovery and development of oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting Phase 2 clinical trials in fibrosis-driven diseases with high unmet need: idiopathic pulmonary fibrosis (NCT05671835) and hepatocellular carcinoma (NCT05440708). The content above comes from the network. if any infringement, please contact us to modify.

临床结果免疫疗法

2025-03-23

·药明康德

旨在逆转肺损伤的干细胞疗法进入临床；使无进展生存期优于标准治疗的小分子疗法…… | 一周盘点

▎药明康德内容团队编辑本期看点 1. 小分子白细胞介素-2诱导的T细胞激酶（ITK）抑制剂soquelitinib用于治疗T细胞淋巴瘤的早期临床试验结果积极，18个月的无进展生存率优于标准治疗药物。 2. PLN-101095联用PD-1抑制剂治疗免疫检查点抑制剂（ICI）难治性晚期或转移性实体瘤患者，在一项1期临床试验中使50%的患者达到确认的部分缓解（PR）。 3. SMSbiotech公司旨在逆转慢性阻塞性肺疾病（COPD）患者肺损伤或恢复肺功能的干细胞疗法获批在澳大利亚启动1期临床试验。药明康德内容团队整理 Soquelitinib：公布1/1b期临床试验数据 Corvus Pharmaceuticals公司公布了其小分子白细胞介素-2诱导的T细胞激酶（ITK）抑制剂soquelitinib用于治疗T细胞淋巴瘤的1/1b期临床试验数据。ITK是一种主要表达于T细胞中的酶，在T细胞和自然杀伤（NK）细胞的免疫功能中起重要作用。通过抑制ITK，soquelitinib有望抑制自身免疫和炎症反应。此次公布的结果显示，在23名疗效可评估的患者中，有9例（39%）患者达到客观缓解，包括6例完全缓解（CR）和3例PR。9例达到客观缓解患者的中位缓解持续时间（DOR）为17.2个月，估计的中位无进展生存期（PFS）为6.2个月。18个月的无进展生存率为30%，优于标准治疗药物，后者在同一时间段内的无进展生存率＜20%。安全性方面，soquelitinib的耐受性良好，没有报告新的安全性信号、药物中断或剂量减少。 PLN-101095：公布1期临床试验的中期数据 Pliant Therapeutics公司公布了其正在进行的1期临床试验的前三个队列的数据，该试验评估了PLN-101095联用PD-1抑制剂pembrolizumab治疗ICI难治性晚期或转移性实体瘤患者的效果。PLN-101095是Pliant Therapeutics公司开发的口服靶向整合素αvβ8和αvβ1的双重选择性小分子抑制剂，用于治疗对免疫检查点抑制剂耐药的实体肿瘤。TGF-β信号传导的增加被认为是肿瘤细胞对免疫检查点抑制剂耐药的潜在原因。PLN-101095靶向肿瘤微环境中表达的整合素αvβ8和αvβ1，能够调节TGF-β的活性，旨在恢复肿瘤对PD-1/PD-L1抑制剂的敏感性。此次公布的结果显示，在所有测试剂量中，PLN-101095通常耐受性良好。在接受PLN-101095治疗的6名患者中，观察到3名（50%）患者达到了确认的PR，包括1名非小细胞肺癌患者（第18周时肿瘤缩小74%）、1名胆管癌患者（第42周时肿瘤缩小48%）和1名黑色素瘤患者（第27周时肿瘤缩小42%）。 Small Mobile Stem cell：获批在澳大利亚启动1期临床试验 SMSbiotech公司宣布，其创新的干细胞疗法Small Mobile Stem cell获批在澳大利亚启动1期临床试验，用于评估其治疗COPD的安全性和耐受性。这也是该疗法首次在人体中进行试验。COPD是一种逐步损害呼吸功能的进行性肺病，现有疗法的目的主要集中在缓解症状上，而不是逆转损伤或恢复肺功能。SMSbiotech公司的干细胞技术旨在通过再生受损的肺泡组织，有望修复组织损伤并恢复肺功能。 BB-301：公布1b/2a期临床试验中前3例患者的数据 Benitec Biopharma公司公布了其开发用于治疗眼咽肌营养不良（OPMD）的沉默和取代基因疗法BB-301在1b/2a期临床试验中的前3例患者的积极数据。该疗法利用一种新型的、经过改良的AAV9载体，表达一种独特的、单一的双功能构建体，从而能够促进密码子优化的PABPN1基因和两个针对PABPN1突变体siRNA的共同表达。这两个siRNA被塑造成微RNA骨架，以抑制有缺陷的PABPN1突变体的表达，同时允许表达经过密码子优化的PABPN1基因，用PABPN1蛋白的功能性版本取代突变体。此次公布的结果显示，所有3名受试者的总吞咽困难症状负担均显著减轻。1号患者和2号患者在接受BB-301治疗后12个月均实现了持久且具有临床意义的吞咽功能改善，其中2号患者在症状负担显著减轻后达到了临床上正常的吞咽状态。3号患者接受BB-301治疗后3个月观察到显著的吞咽功能改善，随后也达到了临床上正常的吞咽状态。安全性方面，未报告严重不良事件。 TTI-101：公布1期临床试验数据 Tvardi Therapeutics宣布，其口服小分子STAT3抑制剂TTI-101在晚期实体瘤患者中的首个人体1期研究结果已发表在Clinical Cancer Research上。STAT3是一种关键的调节蛋白，长期以来一直被认为是肿瘤学的主要靶标。临床前实验中，TTI-101展现优异的药代动力学特征、减弱pY705-STAT3磷酸化的效果，并在头颈癌、肺癌、乳腺癌和肝癌的动物模型中表现出抗癌活性。此次公布的结果显示，TTI-101的耐受性良好，未观察到剂量限制性毒性或致命的治疗相关不良事件（TRAE）。在41例疗效可评估的患者中，有5例（12%）达到了确认的PR，17例（41%）达到了疾病稳定（SD）。17例肝细胞癌患者中有3例（18%）达到了确认的PR。另外2例获得确认的PR的患者分别患有卵巢癌和胃癌。 LX-101：公布1a期临床试验数据 Lirum Therapeutics公司宣布，其创新药物LX-101治疗甲状腺眼病（TED）的首批数据获选在北美神经眼科学会（NANOS）年会上展示。LX-101是一种针对胰岛素样生长因子-1受体（IGF-1R）的靶向治疗，能够将甲氨蝶呤（一种广泛用于自身免疫疾病的药物，在TED中有使用历史）精确递送到导致疾病的关键效应细胞（如IGF-1R+活化的T细胞和眼眶成纤维细胞），有望提供一种新颖且差异化的方法来治疗TED。此次公布的结果表明，LX-101能够有效靶向驱动TED发病机制的潜在过程，包括减少或控制TED患者中异常活跃的眶成纤维细胞的功能和增殖、减少关键炎症因子的产生、减少细胞外基质促纤维化成分的产生，以及调节TED患者中异常活跃T细胞的功能和行为。 PBGENE-HBV：IND申请获得FDA许可 Precision BioSciences公司宣布，美国FDA已批准PBGENE-HBV的IND申请。PBGENE-HBV旨在通过消除乙型肝炎病毒（HBV）的共价闭合环状DNA（cccDNA），同时灭活整合在肝细胞中的HBV DNA，以达到功能性治愈慢性乙型肝炎的目的。根据新闻稿，PBGENE-HBV是首个在美国获批进入临床阶段的在研体内基因编辑疗法。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料（可上下滑动查看） [1] Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B. Retrieved March 21, 2025, from https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-clearance-investigational-new [2] Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. Retrieved March 21, 2025, from https://www.benitec.com/for-investors/news-events/press-releases/detail/130/benitec-biopharma-reports-positive-interim-clinical-results-for-three-subjects-treated-with-bb-301-in-phase-1b2a-study-to-be-presented-at-the-2025-muscular-dystrophy-association-clinical-scientific-conference [3] Anocca Announces Authorisation of Clinical Trial Application to Start First In-Human Trial in Advanced Pancreatic Cancer. Retrieved March 21, 2025, from https://www.globenewswire.com/news-release/2025/03/17/3043419/0/en/Anocca-Announces-Authorisation-of-Clinical-Trial-Application-to-Start-First-In-Human-Trial-in-Advanced-Pancreatic-Cancer.html [4] SMSbiotech Receives Green Light for Phase I Clinical Trial in Australia, Targeting COPD. Retrieved March 21, 2025, from https://www.businesswire.com/news/home/20250318995283/en/SMSbiotech-Receives-Green-Light-for-Phase-I-Clinical-Trial-in-Australia-Targeting-COPD [5] Lirum Therapeutics Announces Debut of LX-101 Results in Thyroid Eye Disease, Selected for Presentation at the 2025 NANOS Annual Meeting. Retrieved March 21, 2025, from https://www.lirumtx.com/copy-of-2025-03-04 [6] Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors. Retrieved March 21, 2025, from https://www.globenewswire.com/news-release/2025/03/17/3043649/0/en/Pliant-Therapeutics-Announces-Interim-Phase-1-Data-for-PLN-101095-in-Patients-with-Immune-Checkpoint-Inhibitor-Refractory-Advanced-Solid-Tumors.html [7] Tvardi Announces Publication of First-in-Human Study of TTI-101. Retrieved March 21, 2025, from https://tvarditherapeutics.com/2025/03/19/tvardi-announces-publication-of-first-in-human-study-of-tti-101/ [8] Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma. Retrieved March 21, 2025, from https://investor.corvuspharma.com/news-releases/news-release-details/corvus-pharmaceuticals-announces-presentation-additional-data [9] Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. Retrieved March 21, 2025, from https://ir.satellos.com/news/news-details/2025/Satellos-Presents-Initial-Data-from-the-Phase-1-Trial-of-SAT-3247-at-the-2025-Muscular-Dystrophy-Association-Clinical--Scientific-Conference/default.aspx [10] Pacylex Pharmaceuticals Announces the first Acute Myeloid Leukemia (AML) patient dosed with zelenirstat in a new Phase 1/2 clinical trial. Retrieved March 21, 2025, from https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-announces-the-first-acute-myeloid-leukemia-aml-patient-dosed-with-zelenirstat-in-a-new-phase-1-2-clinical-trail [11] First human safety and pharmacokinetic study of a plasmalogen augmentation therapy published by MLD. Retrieved March 21, 2025, from https://med-life.ca/news1/2025/3/6/first-human-safety-and-pharmacokinetic-study-of-a-plasmalogen-augmentation-therapy-published-by-mld [12] Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease. Retrieved March 21, 2025, from https://www.globenewswire.com/news-release/2025/03/14/3042895/0/en/Gain-Therapeutics-Doses-First-Participant-in-Phase-1b-Clinical-Trial-of-GT-02287-in-Parkinson-s-Disease.html [13] Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months. Retrieved March 17, 2025, from https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-long-term-clinical-data-phase-12 [14] Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial. Retrieved March 17, 2025, from https://aviditybiosciences.investorroom.com/2025-03-17-Avidity-Biosciences-Announces-Positive-Topline-Del-zota-Data-Demonstrating-Consistent,-Statistically-Significant-Improvements-in-Dystrophin,-Exon-Skipping-and-Creatine-Kinase-in-People-Living-with-Duchenne-Muscular-Dystrophy-Amenable-to-Exon-44 [15] Angitia Biopharmaceuticals Presents Data from Phase 1/2 Study of AGA111 at 2025 AAOS Annual Meeting. Retrieved March 21, 2025, from https://www.globenewswire.com/news-release/2025/03/18/3044330/0/en/Angitia-Biopharmaceuticals-Presents-Data-from-Phase-1-2-Study-of-AGA111-at-2025-AAOS-Annual-Meeting.html [16] MAXONA PHARMACEUTICALS ANNOUNCES MAX-OO1 PHASE 1 CLINICAL PROGRAM RESULTS. Retrieved March 21, 2025, from https://www.prnewswire.com/news-releases/maxona-pharmaceuticals-announces-max-oo1-phase-1-clinical-program-results-302403703.html [17] Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers. Retrieved March 21, 2025, from https://www.globenewswire.com/news-release/2025/03/19/3045315/0/en/Acumen-Pharmaceuticals-Announces-Topline-Results-from-Phase-1-Study-of-Subcutaneous-Formulation-of-Sabirnetug-in-Healthy-Volunteers.html [18] Altesa BioSciences Announces Clearance of Investigational New Drug (IND) Application for Vapendavir. Retrieved March 21, 2025, from https://www.prnewswire.com/news-releases/altesa-biosciences-announces-clearance-of-investigational-new-drug-ind-application-for-vapendavir-302406110.html [19] Pathos AI Doses First Patient in Phase 1b/2a Clinical Trial of Pocenbrodib, a CBP/p300 Inhibitor. Retrieved March 21, 2025, from https://www.globenewswire.com/news-release/2025/03/20/3046174/0/en/Pathos-AI-Doses-First-Patient-in-Phase-1b-2a-Clinical-Trial-of-Pocenbrodib-a-CBP-p300-Inhibitor.html [20] Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219. Retrieved March 21, 2025, from https://www.sitryx.com/news/sitryx-initiates-phase-1-clinical-trial-of-potential-disease-modifying-treatment-for-atopic-dermatitis-syx-5219 [21] Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab. Retrieved March 21, 2025, from https://www.globenewswire.com/news-release/2025/03/18/3044457/0/en/Indaptus-Therapeutics-Initiates-Phase-1-Combination-Study-of-Decoy20-with-PD-1-Checkpoint-Inhibitor-Tislelizumab.html [22] STCube receives IND approval for nelmastobart in metastatic colorectal cancer in Korea. Retrieved March 21, 2025, from https://www.koreabiomed.com/news/articleView.html?idxno=27004 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床1期临床结果细胞疗法临床2期

2024-10-02

·tvarditherapeutics.com

Tvardi Therapeutics Announces Presentation of TTI-101 Preclinical Data Providing Mechanistic Rationale for Phase 2 REVERT IPF Clinical Trial at CHEST 2024

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and Terms of Use.

临床2期

100 项与 C-188-9 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性头颈部鳞状细胞癌	临床2期	-	The University of Texas MD Anderson Cancer Center	2025-12-31
胰腺导管腺癌	临床2期	美国	Tvardi Therapeutics, Inc.初创企业	2024-01-16
特发性肺纤维化	临床2期	美国	Tvardi Therapeutics, Inc.初创企业	2023-05-15
局部晚期肝细胞癌	临床2期	美国	Tvardi Therapeutics, Inc.初创企业	2023-03-23
晚期乳腺癌	临床1期	美国	Tvardi Therapeutics, Inc.初创企业	2023-01-09
HR阳性/HER2阴性乳腺癌	临床1期	美国	Tvardi Therapeutics, Inc.初创企业	2023-01-09
局部晚期乳腺癌	临床1期	美国	Tvardi Therapeutics, Inc.初创企业	2023-01-09
PIK3CA突变/HR阳性/HER2阴性乳腺癌	临床1期	美国	Tvardi Therapeutics, Inc.初创企业	2023-01-09
乳腺癌	临床1期	美国	The University of Texas MD Anderson Cancer Center	2017-11-15
乳腺癌	临床1期	美国	Tvardi Therapeutics, Inc.初创企业	2017-11-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03195699 (Pubmed) 人工标引	临床1期	晚期恶性实体瘤	64	TTI-101 3.2 (DL1), 6.4 (DL2), 12.8 (DL3), and 25.6 (DL4) mg/kg/day	醖餘製膚積壓淵憲構糧(鏇膚餘夢醖製網繭築襯) = 鏇簾遞壓膚獵繭襯網壓製構鑰齋選遞衊鹽廠糧 (憲獵繭鹹製齋鏇夢積淵 ) 更多	积极	2025-03-17
NCT03195699 (ASCO 12023 \| ASCO 22023) 人工标引	临床1期	HR阳性/HER2低表达实体瘤	39	TTI-101	積遞網範遞襯鏇簾襯鏇(壓衊鏇鹹鹽憲鑰窪網艱) = No dose limiting toxicities (DLTs), or fatal treatment-related adverse events (TRAEs) were observed. 範鹽醖觸鬱淵艱艱廠夢 (廠鏇網築窪築糧膚夢醖 ) 更多	积极	2023-05-31
NCT03195699 (ASCO 12023 \| ASCO 22023) 人工标引	临床1期	HR阳性/HER2低表达实体瘤	39	TTI-101 (hepatocellular carcinoma)		积极	2023-05-31